Drospirenone/ethinyl estradiol tablets in a dose of 3 mg/0.03 mg, had US sales of approximately US$137.6 million for the 12 months ending 30 June 2015, according to IMS Health.

There has been some controversy over Bayer’s Yaz and Yasmin range in the past with the German pharma giant suing Teva Pharmaceutical Industries for claiming that its generic oral contraceptive, Gianvi, was the same as Yaz [1, 2].

Currently, Mylan has 266 ANDAs pending FDA approval representing US$99.5 billion in annual brand-name drug sales.  Fifty of these pending ANDAs are potential first-to-file opportunities, representing US$33.4 billion in annual brand-name drug sales for 2014, according to IMS Health.

Related article
Mylan launches generic asthma inhaler in UK

References
1. GaBI Online - Generics and Biosimilars Initiative. Bayer sues Teva over generic Yaz contraceptive [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 Sep 11]. Available from: www.gabionline.net/Generics/News/Bayer-sues-Teva-over-generic-Yaz-contraceptive
2. GaBI Online - Generics and Biosimilars Initiative. Teva changes generic Yaz contraceptive label [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 Sep 11]. Available from: www.gabionline.net/Generics/News/Teva-changes-generic-Yaz-contraceptive-label

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2015 Pro Pharma Communications International. All Rights Reserved.